198 related articles for article (PubMed ID: 29383359)
1. Importance of protein flexibility in molecular recognition: a case study on Type-I1/2 inhibitors of ALK.
Kong X; Sun H; Pan P; Zhu F; Chang S; Xu L; Li Y; Hou T
Phys Chem Chem Phys; 2018 Feb; 20(7):4851-4863. PubMed ID: 29383359
[TBL] [Abstract][Full Text] [Related]
2. Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors.
Kong X; Pan P; Li D; Tian S; Li Y; Hou T
Phys Chem Chem Phys; 2015 Feb; 17(8):6098-113. PubMed ID: 25644934
[TBL] [Abstract][Full Text] [Related]
3. An integrated molecular modeling approach for in silico design of new tetracyclic derivatives as ALK inhibitors.
Peddi SR; Sivan SK; Manga V
J Recept Signal Transduct Res; 2016 Oct; 36(5):488-504. PubMed ID: 26758803
[TBL] [Abstract][Full Text] [Related]
4. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
[TBL] [Abstract][Full Text] [Related]
5. Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib-resistant ALK mutations.
Tu J; Song LT; Liu RR; Zhai HL; Wang J; Zhang XY
J Cell Biochem; 2019 Jan; 120(1):562-574. PubMed ID: 30191596
[TBL] [Abstract][Full Text] [Related]
6. Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer.
Ni Z; Zhang TC
J Mol Model; 2015 Jul; 21(7):175. PubMed ID: 26084268
[TBL] [Abstract][Full Text] [Related]
7. Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors.
Tu J; Song LT; Zhai HL; Wang J; Zhang XY
Int J Biol Macromol; 2018 Oct; 118(Pt A):1149-1156. PubMed ID: 30001602
[TBL] [Abstract][Full Text] [Related]
8. Importance of Incorporating Protein Flexibility in Molecule Modeling: A Theoretical Study on Type I
Shen C; Liu H; Wang X; Lei T; Wang E; Xu L; Yu H; Li D; Yao X
Front Pharmacol; 2019; 10():345. PubMed ID: 31024312
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
10. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK.
Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J
J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251
[TBL] [Abstract][Full Text] [Related]
11. Importance of protein flexibility on molecular recognition: modeling binding mechanisms of aminopyrazine inhibitors to Nek2.
Tang X; Wang Z; Lei T; Zhou W; Chang S; Li D
Phys Chem Chem Phys; 2018 Feb; 20(8):5591-5605. PubMed ID: 29270587
[TBL] [Abstract][Full Text] [Related]
12. Scaffold hopping identifies 6,8-disubstituted purines as novel anaplastic lymphoma kinase inhibitors.
Schlütke L; Immer M; Preu L; Totzke F; Schächtele C; Kubbutat MHG; Kunick C
Eur J Pharm Biopharm; 2018 May; 126():89-94. PubMed ID: 28315448
[TBL] [Abstract][Full Text] [Related]
13. Molecular Mechanism Behind the Resistance of the G1202R-Mutated Anaplastic Lymphoma Kinase to the Approved Drug Ceritinib.
Chen C; He Z; Xie D; Zheng L; Zhao T; Zhang X; Cheng D
J Phys Chem B; 2018 May; 122(17):4680-4692. PubMed ID: 29648831
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Low Micromolar Dual Inhibitors for Wild Type and L1196M Mutant of Anaplastic Lymphoma Kinase through Structure-Based Virtual Screening.
Shin S; Mah S; Hong S; Park H
J Chem Inf Model; 2016 Apr; 56(4):802-10. PubMed ID: 27014917
[TBL] [Abstract][Full Text] [Related]
15. Assessing an ensemble docking-based virtual screening strategy for kinase targets by considering protein flexibility.
Tian S; Sun H; Pan P; Li D; Zhen X; Li Y; Hou T
J Chem Inf Model; 2014 Oct; 54(10):2664-79. PubMed ID: 25233367
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Potent ALK Inhibitors Using Pharmacophore-Informatics Strategy.
James N; Ramanathan K
Cell Biochem Biophys; 2018 Jun; 76(1-2):111-124. PubMed ID: 28477056
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.
Gunby RH; Ahmed S; Sottocornola R; Gasser M; Redaelli S; Mologni L; Tartari CJ; Belloni V; Gambacorti-Passerini C; Scapozza L
J Med Chem; 2006 Sep; 49(19):5759-68. PubMed ID: 16970400
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations reveal the allosteric effect of F1174C resistance mutation to ceritinib in ALK-associated lung cancer.
Ni Z; Wang X; Zhang T; Jin RZ
Comput Biol Chem; 2016 Dec; 65():54-60. PubMed ID: 27764703
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Structurally Diverse Anaplastic Lymphoma Kinase Inhibitors Based on Pharmacophore Modeling, Virtual Screening and Molecular Docking.
You R; Zhou L; Zhong L; Li X; Zhou S; Tian Y
Comb Chem High Throughput Screen; 2016; 19(9):691-704. PubMed ID: 27487788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]